Системная красная волчанка и в и тамин D
https://doi.org/10.14412/1996-7012-2015-2-57-65
Аннотация
В обзоре представлены данные литературы о частоте гиповитаминоза D при системной красной волчанке (СКВ), проанализирована ассоциация клинико-лабораторных параметров заболевания и уровня витамина D, рассмотрены возможности терапевтического применения его метаболитов. Дефицит витамина D является весьма распространенным патологическим состоянием, создающим предпосылки для развития широкого круга болезней. Низкий сывороточный уровень витамина D может быть связан с недостаточной солнечной экспозицией, генетической предрасположенностью (полиморфизм рецепторов витамина D) и алиментарными факторами, а также сопутствовать аутоиммунным заболеваниям. Выявленные иммуномодуляторные свойства витамина D представляют интерес с точки зрения возможного участия данного гормона в патогенезе аутоиммунных заболеваний. Ряд исследователей предлагает рассматривать витамин D как модифицируемый фактор окружающей среды, участвующий в развитии аутоиммунных заболеваний. Имеются данные о связи низкого сывороточного уровня 25(ОН)D c риском развития, активностью, тяжестью и прогнозом некоторых ревматических заболеваний (в первую очередь ревматоидного артрита и СКВ), что требует дальнейшего изучения. Антирезорбтивное, противовоспалительное и иммуномодулирующее действие метаболитов витамина D обосновывает целесообразность их применения при хронических воспалительных заболеваниях в комбинации с традиционными базисными средствами.
Об авторе
Н. Г. КлюквинаРоссия
Литература
1. Gatenby P, Lucas R, Swaminathan A. Vitamin D deficiency and risk for rheumatic diseases. Curr Opin Rheumatol. 2013 Mar;25(2):184–91. doi: 10.1097/BOR.0b013e32835cfc16.
2. Holick MF. Vitamin D deficiency. N Engl J Med. 2007 Jul 19;357(3):266–81.
3. Cutolo M. Vitamin D and autoimmune rheumatis diseases. Rheumatology (Oxford). 2009 Mar;48(3):210–2. doi: 10.1093/rheumatology/ken394. Epub 2008 Oct 17.
4. Holick MF, Garabedian M. Vitamin D: photobiology, metabolism, mechanism of action and clinical applications. In: Favus MJ, et al, editors. Primer on the metabolic bone disease and disorders of mineral metabolism. 6th ed. Washington, DC: American Society for Bone and Mineral Research; 2006. P. 129–137.
5. DeLuca HF. Overview of general physiologic features and functions of vitamin. Am J Clin Nutr. 2004 Dec;80(6 Suppl): 1689S–96S.
6. Торопцова НВ, Аникин СГ. Витамин D и ревматоидный артрит: что мы знаем сегодня? Научно-практическая ревматология. 2011;(3):46–51. [Toroptsova NV, Anikin SG. Vitamin D and rheumatoid arthritis: What do we know today? Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2011;(3):46–51. (In Russ.)]. DOI: ttp://dx.doi.org/10.14412/1995-4484- 2011-573
7. Ibrahim MH, Bakheet MS, Abdel-Safer KA, Shakoor MA. Relationship between vitamin D and disease activity in some rheumatic diseases. Int J Nutr Metab 2013;5(7):114–27. DOI: 10.5897/IJNAM2013.0153
8. Насонов ЕЛ. Кальций и витамин D: роль в профилактике и лечении остеопороза и других заболеваний человека. Consilium medicum. 1999; 1(5):212–4. [Nasonov EL. Calcium and vitamin D: role in the prevention and treatment of osteoporosis and other diseases. Consilium medicum. 1999; 1(5):212–4. (In Russ.)].
9. Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev. 2005 Aug;26(5):662–87. Epub 2005 Mar 29.
10. Mathieu C, Adorini L. The coming of age of 1,25-dihydroxyvitamin D3 analogs as immunomodulatory agents. Trends Mol Med. 2002 Apr;8(4):174–9.
11. Dawson-Hughes B, Heaney RP, Holick MF, et al. Estimates of optimal vitamin D status. Osteoporos Int. 2005 Jul;16(7):713–6. Epub 2005 Mar 18.
12. Holick MF. Vitamin D deficiency. N Engl J Med. 2007 Jul 19;357(3):266–81.
13. Gordon CM, DePeter KC, Feldman HA, et al. Prevalence of vitamin D deficiency among healthy adolescents. Arch Pediatr Adolesc Med. 2004 Jun;158(6):531–7.
14. Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med. 2008 Aug 11;168(15):1629–37. doi: 10.1001/archinte.168.15.1629.
15. Cutolo M, Otsa K. Review: vitamin D, immunity amd lupus. Lupus. 2008 Jan;17(1):6–10.
16. Nair R, Maseeh A. Vitamin D: the «sunshine » vitamin. J Pharmacol Pharmacother. 2012 Apr;3(2):118–26. doi: 10.4103/0976-500X.95506.
17. Autier P, Gandini S. Vitamin D supplementation and total mortality: A meta-analysis of randomized controlled trials. Arch Intern Med. 2007 Sep 10;167(16):1730–7.
18. Muller K, Kriegbaum NJ, Baslund B, et al. Vitamin D3 metabolism in patients with heumatic diseases: low serum levels of 25-hydroxyvitamin D3 in patients with systemic lupus erythematosus. Clin Rheumatol. 1995 Jul;14(4):397–400.
19. Bikle DD. What is new in vitamin D: 2006–2007. Curr Opin Rheumatol. 2007 Jul;19(4):383–8.
20. Kamen D, Aranow C. Vitamin D in systemic lupus erythematosus. Curr Opin Rheumatol. 2008 Sep;20(5):532–7. doi: 10.1097/BOR.0b013e32830a991b.
21. Kamen DL, Cooper GS, Bouali H, et al. Vitamin D deficiency in systemic lupus rythematosus. Autoimmun Rev. 2006 Feb;5(2):114–7. Epub 2005 Jun 21.
22. Mok СС, Birmingham DJ, Ho LY, et al. Vitamin D deficiency as marker for disease activity and damage in systemic lupus erythematosus: a comparison with anti-dsDNA and anti-C1q. Lupus. 2012 Jan;21(1):36–42. doi: 10.1177/0961203311422094. Epub 2011 Oct 12.
23. Carvalho JF, Blank M, Kiss E, et al. Antivitamin D, vitamin D in SLE: preliminary results. Ann N Y Acad Sci. 2007 Aug;1109:550–7.
24. Le Goaziou MF, Contardo G, Dupraz C, et al. Risk factors for vitamin D deficiency in women aged 20–50 years consulting in general practice: a crosssectional study. Eur J Gen Pract. 2011 Sep;17(3):146–52. doi: 10.3109/13814788.2011.560663. Epub 2011 Feb 25.
25. Ben-Zvi I, Aranow C, Mackay M, et al. The impact of vitamin D on Dendritic cell function in patients with systemic lupus erythematosus. PLoS One. 2010 Feb 16;5(2): e9193. doi: 10.1371/journal.pone.0009193.
26. Amital H, Szekanecz Z, Szü cs G, et al. Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D? Ann Rheum Dis. 2010 Jun;69(6):1155–7. doi: 10.1136/ard.2009.120329. Epub 2010 May 3.
27. Cutillas-Marco E, Morales-Suarez-Varela M, Marquina-Vila A, Grant W. Serum 25-hydroxyvitamin D levels in patients with cutaneous lupus erythematosus in a Mediterranean region. Lupus. 2010 Jun;19(7):810–4. doi: 10.1177/09612033 09360807. Epub 2010 Mar 19.
28. Kim HA, Sung JM, Jeon JY, et al. Vitamin D may not be a good marker of disease activity in Korean patients with systemic lupus erythematosus. Rheumatol Int. 2011 Sep;31(9):1189–94. doi: 10.1007/s00296-010-1442-1. Epub 2010 Mar 30.
29. Szodoray P, Tarr T, Bazso A, et al. The immunopathological role of vitamin D in patients with SLE: data from a single centre registry in Hungary. Scand J Rheumatol. 2011 Mar;40(2):122–6. doi: 10.3109/03009742. 2010.507220. Epub 2010 Oct 26.
30. Toloza SM, Cole DE, Gladman DD, et al. Vitamin D insufficiency in a large female SLE cohort. Lupus. 2010 Jan;19(1):13–9. doi: 10.1177/0961203309345775. Epub 2009 Nov 6.
31. Cusack C, Danby C, Fallon JC, et al. Photoprotective behaviour and sunscreen use: impact on vitamin D levels in cutaneous lupus erythematosus. Photodermatol Photoimmunol Photomed. 2008 Oct;24(5):260–7. doi: 10.1111/j.1600- 0781.2008.00373.x.
32. Kamen DL, Cooper GS, Bouali H, et al. Vitamin D deficiency in systemic lupus rythematosus. Autoimmun Rev. 2006 Feb;5(2):114–7. Epub 2005 Jun 21.
33. Ruiz-Irastorza G, Egutide MV, Olivares N, et al. Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatology (Oxford). 2008 Jun;47(6):920–3. doi: 10.1093/rheumatology/ ken121. Epub 2008 Apr 14.
34. Ruiz-Irastorza G, Gordo S, Olivares N, et al. Changes in vitamin D levels in patients with systemic lupus erythematosus: effects on fatigue, disease activity and damage. Arthritis Care Res (Hoboken). 2010 Aug;62(8):1160–5. doi: 10.1002/acr.20186.
35. Wu PW, Rhew EY, Dyer AR, et al. 25-Hydroxyvitamin D and cardiovascular risk factors in women with systemic lupus erythematosus. Arthritis Rheum. 2009 Oct 15;61(10):1387–95. doi: 10.1002/art.24785.
36. Reynolds JA, Hague S, Berry JL, et al. 25-hydroxyvitamin D deficiency is associated with increased aortic stiffness in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2012 Mar;51(3):544–51. doi: 10.1093/rheumatology/ker352. Epub 2011 Nov 24.
37. Mok CC, Birmingham DJ, Leung HW, et al. Vitamin D levels in Chinese patients with systemic lupus erythematosus: relationship with disease activity, vascular risk factors and atherosclerosis. Rheumatology (Oxford). 2012 Apr;51(4):644–52. doi: 10.1093/rheumatology/ker212. Epub 2011 Jun 29.
38. Birmingham DJ, Hebert LA, Song H, et al. Evidence that abnormally large seasonal declines in vitamin D status may trigger SLE flare in non-African Americans. Lupus. 2012Jul;21(8):855–64. doi: 10.1177/0961203 312439640. Epub 2012 Mar 20.
39. Mandal M, Tripathy R, Panda AK, et al. Vitamin D levels in Indian systemic lupus erythematosus patients: association with disease activity index and interferon alpha. Arthritis Res Ther. 2014 Feb 10;16(1):R49. doi: 10.1186/ar4479.
40. O’Regan S, Chesney RW, Hamstra A, et al. Reduced serum 1,25-(OH)2 vitamin D3 levels in prednisone-treated adolescents with systemic lupus erythematosus. Acta Paediatr Scand. 1979 Jan;68(1):109–11.
41. Husiman AM, White KP, Algra A, et al. Vitamin D levels in women with systemic lupus erythematosus and fibromyalgia. J Rheumatol. 2001 Nov;28(11):2535–9.
42. Broder AR, Tobin JN, Putterman C. Disease-specific definitions of vitamin D deficiency need to be established in autoimmune and non-autoimmune chronic diseases: a retrospective comparison of three chronic diseases. Arthritis Res Ther. 2010;12(5):R191. doi: 10.1186/ar3161. Epub 2010 Oct 14.
43. Thudi A, Yin S, Wandstrat AE, et al. Vitamin D levels and disease status in Texas patients with systemic lupus erythematosus. Am J Med Sci. 2008 Feb;335(2):99–104. doi: 10.1097/MAJ.0b013e318134eeb6.
44. Reichel H, Koeffler HP, Tobler A, Norman AW. 1 alpha,25-dihydroxyvitamin D3 inhibits gamma-interferon synthesis by normal human peripheral blood lymphocytes. Proc Natl Acad Sci USA. 1987 May;84(10):3385–9.
45. Griffin MD, Lutz WH, Phan VA, et al. Potent inhibition of dendritic cell differentiation and maturation by vitamin D analogs. Biochem Biophys Res Commun. 2000 Apr 21;270(3):701–8.
46. Dobnig H, Pilz S, Scharnagl H, et al. Independent association of low serum 25- hydroxyvitamin D and 1,25-dihydroxyvitamin D Levels with all-cause and cardiovascular mortality. Arch Intern Med. 2008 Jun 23;168(12):1340–9. doi: 10.1001/archinte. 168.12.1340.
47. Scragg R, Jackson R, Holdaway IM, et al. Myocardial infarction is inversely associated with plasma 25-hydroxyvitamin D3 levels: a community-based study. Int J Epidemiol. 1990 Sep;19(3):559–63.
48. Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008 Jan 29;117(4):503–11. doi: 10.1161/CIRCULATIONAHA. 107.706127. Epub 2008 Jan 7.
49. Jablonski KL, Chonchol M, Pierce GL, et al. 25-Hydroxyvitamin D deficiency is associated with inflammation-linked vascular endothelial dysfunction in middle-aged and older adults. Hypertension. 2011 Jan;57(1): 63–9. doi: 10.1161/HYPERTENSIONAHA. 110.160929. Epub 2010 Nov 29.
50. Pilz S, Henry R, Snijder M, et al. 25-Hydroxyvitamin D is not associated with carotid intima-media thickness in older men and women. Calcif Tissue Int. 2009 May;84(5):423–4. doi: 10.1007/s00223-009-9238-6. Epub 2009 Mar 24.
51. Reis JP, von Muhlen D, Michos ED, et al. Serum vitamin D, parathyroid hormone levels, and carotid atherosclerosis. Atherosclerosis. 2009 Dec;207(2):585–90. doi: 10.1016/j.atherosclerosis.2009.05.030. Epub 2009 Jun 6.
52. Tarcin O, Yavuz DG, Ozben B, et al. Effect of vitamin D deficiency and replacement on endothelial function in asymptomatic subjects. J Clin Endocrinol Metab. 2009 Oct;94(10):4023–30. doi: 10.1210/jc.2008–1212. Epub 2009 Jul 7.
53. Watson KE, Abrolat ML, Malone LL, et al. Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation. 1997 Sep 16;96(6):1755–60.
54. Bruce IN, Urowitz MB, Gladman DD, et al. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum. 2003 Nov;48(11):3159–67.
55. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001 Oct;44(10):2331–7.
56. Angel K, Provan SA, Gulseth HL, et al. Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study. Hypertension. 2010 Feb;55(2):333–8. doi: 10.1161/HYPERTENSIONHA.109.143982. Epub 2009 Dec 28.
57. Vlachopoulos C, Aznaouridis K, tefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010 Mar 30;55(13): 1318–27. doi: 10.1016/j.jacc.2009.10.061.
58. Lertratanakul A, Wu P, Dyer A, et al. 25-hydroxyvitamin D and cardiovascular disease in patients with systemic lupus erythematosus: data from a large international inception cohort. Arthritis Care Res (Hoboken). 2014 Aug;66(8):1167–76. doi: 10.1002/acr.22291.
59. Luong K, Nguyen LT. The beneficial role of vitamin D in systemic lupus erythematosus (SLE). Clin Rheumatol. 2012 Oct;31(10):1423–35. doi: 10.1007/s10067- 012-2033-1. Epub 2012 Jul 17.
60. Alarcon GS, Friedman AW, Straaton KV, et al. Systemic lupus erythematosus in three ethnic groups: III. A comparison of characteristics early in the natural history of the LUMINA cohort. Lupus. 1999;8(3):197–209.
61. Birmingham DJ, Hebert LA, Song H, et al. Evidence that abnormally large seasonal declines in vitamin D status may trigger SLE flare in non-African Americans. Lupus. 2012 Jul;21(8):855–64. doi: 10.1177/0961203312 439640. Epub 2012 Mar 20.
62. Vijay J, Kapil U. Vitamin D deficiency and its health consequences – a review. Indian J Community Health. 2012;24:232–236.
63. Malaviya AN, Singh RR, Singh YN, et al. Prevalence of systemic lupus erythematosus in India. Lupus. 1993 Apr;2(2):115–8.
64. Kumar A, Malaviya AN, Singh RR, et al. Survival in patients with systemic lupus rythematosus in India. Rheumatol Int. 1992;12(3):107–9.
65. Murali R, Jeyaseelan L, Rajaratnam S, et al. Systemic lupus erythematosus in Indian patients: prognosis, survival and life expectancy. Natl Med J India. 1997 Jul-Aug;10(4):159–64.
66. Munoz LE, Schiller M, Zhao Y, et al. Do low vitamin D levels cause problems of waste removal in patients with SLE? Rheumatology (Oxford). 2012 Apr;51(4):585–7. doi: 0.1093/rheumatology/ ker334. Epub 2011 Oct 27.
67. Carrillo-Vico A, Reiter RJ, Lardone PJ, et al. The modulatory role of melatonin on immune responsiveness. Curr Opin Investig Drugs. 2006 May;7(5):423–31.
68. Ozaki Y, Namura S, Nagahama M, et al. Vitamin-D receptor genotype and renal disorder in Japanese patients with systemic lupus erythematosus. Nephron. 2000 May;85(1):86–91.
69. Huang CM, Wu MC, Wu JY, Tsai FJ. Association of vitamin D receptor gene Bsml polymorphisms in Chinese patients with systemic lupus erythematosus. Lupus. 2002;11(1):31–4.
70. Holick MF, Binkley NC, et al. Evaluation, treatment, and prevention of vitamin d deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011 Jul;96(7):1911–30. doi: 10.1210/jc.2011-0385. Epub 2011 Jun 6.
71. Institute of Medicine. Institute of Medicine dietary reference intakes for calcium and vitamin D. Washington, DC: The National Academics Press; 2011.
72. Rossini M, Bongi SM, La Montagna G, et al. Vitamin D deficiency in rheumatoid arthritis: prevalence, determinants and associations with disease activity and disability. Arthritis Res Ther. 2010;12(6):R216. doi: 10.1186/ar3195. Epub 2010 Nov 29.
73. Bischoff-Ferrari HA, Giovannucci E, Willett WC, et al. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 2006 Jul;84(1):18–28.
74. Abe J, Nakamura K, Takita Y, et al. Prevention of immunological disorders in MRL/l mice by a new synthetic analogue of vitamin D3: 22-oxa-1 alpha, 25-dihydroxyvitamin D3. J Nutr Sci Vitaminol (Tokyo). 1990 Feb;36(1):21–31.
75. Shoenfeld N, Amital H, Shoenfeld Y. The effect of melanism amd vitamin D synthesis on the incidence of autoimmune disease. Nat Clin Pract Rheumatol. 2009 Feb;5(2):99–105. doi: 10.1038/ncprheum0989.
76. Adorini L. Intervention in autoimmunity: the potential of vitamin D receptor agonists. Cell Immunol. 2005 Feb;233(2):115–24.
77. Lemire JM, Ince A, Takashima M. 1,25-Dihydroxyvitamin D3 attenuates the expression of experimental murine lupus of MRL/l mice. Autoimmunity. 1992;12(2):143–8.
78. Koizumi T, Nakao Y, Matsui T, et al. Effects of corticosteroid and 1,25-dihydroxyvitamin D3 administration on lymphoproliferation and autoimmune disease in MRL/MPlpr/ lpr mice. Int Arch Allergy Appl Immunol. 1985;77(4):396–404.
79. Cantorna MT. Vitamin D and autoimmunity: is vitamin D status an environmental factor affecting autoimmune disease prevalence. Proc Soc Exp Biol Med. 2000 Mar;223(3):230–3.
80. van Etten E, Branisteanu DD, Verstuyf A, et al. Analogs of 1,25-dihydroxyvitamin D3 as dose-reducing agents for classical immunosupressants. Transplantation. 2000 May 15;69(9):1932–42.
81. Abou-Raya A, Abou-Raya S, Helmii M. The effect of vitamin D supplementation on inflammatory and hemostatic markers and disease activity in patients with systemic lupus erythematosus: a randomized placebo-controlled trial. J Rheumatol. 2013 Mar;40(3):265–72. doi: 10.3899/jrheum.111594. Epub 2012 Dec 1.
82. Petri M, Bello KJ, Fang H, Magder LS. Vitamin D in systemic lupus erythematosus: modest association with disease activity and the urine protein-to-creatinine ratio. Arthritis Rheum. 2013 Jul;65(7):1865–71. doi: 10.1002/art.37953.
83. Adami S, Giannini S, Bianchi C, et al. Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos Int. 2009 Feb;20(2):239–44. doi: 10.1007/ s00198-008-0650-y. Epub 2008 Jun 13.
84. Geller JL, Hu B, Reed S, et al. Increase in bone mass after correction of vitamin D insufficiency in bisphosphonate-treated patients. Endocr Pract. 2008 Apr;14(3):293–7.
85. Yeap SS, Othman AZ, Zain AA, Chan SP. Vitamin D levels: its relationship to bone mineral density response and disease activity in premenopausal Malaysian systemic lupus erythematosus patients on corticosteroids. Int J Rheum Dis. 2012 Feb;15(1):17–24. doi: 10.1111/j.1756-185X.2011.01653.x. Epub 2011 Aug 31.
86. Ishijima M, Sakamoto Y, Yamanaka M, et al. Minimum required vitamin D level for optimal increase in bone mineral density with alendronate treatment in osteoporotic women. Calcif Tissue Int. 2009 Nov;85(5):398–404. doi: 10.1007/s00223- 009-9295-x. Epub 2009 Oct 1.
87. Dawson-Hughes B, Chen P, Krege JH. Response to teriparatide in patients with baseline 5-hydroxyvitamin D insufficiency or sufficiency. J Clin Endocrinol Metab. 2007 Dec;92(12):4630–6. Epub 2007 Oct 2.
88. Antoniucci DM, Vittinghoff E, Blackwell T, et al. Vitamin D insufficiency does not affect bone mineral density response o taloxifene. J Clin Endocrinol Metab. 2005 Aug;90(8):4566–72. Epub 2005 May 17.
89. Ruiz-Irastorza G, Egurbide MV, Olivares N, et al. Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatology (Oxford). 2008 Jun;47(6):920–3. doi: 10.1093/rheumatology/ken121. Epub 2008 Apr 14.
90. Cusack C, Danby C, Fallon JC, et al. Photoprotective behaviour and sunscreen use: impact on vitamin D levels in cutaneous lupus erythematosus. Photodermatol Photoimmunol Photomed. 2008 Oct;24(5):260–7. doi: 10.1111/j.1600- 0781.2008.00373.x.
91. Cutillas-Marco E, Morales-Suarez-Varela M, Marquina-Vila A, Grant W. Serum 25-hydroxyvitamin D levels in patients with cutaneous lupus erythematosus in a Mediterranean region. Lupus. 2010 Jun;19(7):810–4. doi: 10.1177/09612033 09360807. Epub 2010 Mar 19.
92. M’Barek RB, Dupre T, Tubach F, et al. 25-hydroxyvitamin D status dos not affect the clinical rituximab response in rheumatoid arthritis. Joint Bone Spine. 2014 Jan;81(1):96–7. doi: 10.1016/j.jbspin.2013.04.017. Epub 2013 Jun 21.